Announcement of The Consolidated Financial Report for The 3rd Quarter of Year 2023
2023.11.3
Provided by: TTY BIOPHARM COMPANY LIMITED
| SEQ_NO | 1 | Date of announcement | 2023/11/03 | Time of announcement | 16:46:30 |
| Subject | Announcement of The Consolidated Financial Report for The 3rd Quarter of Year 2023 | ||||
| Date of events | 2022/11/03 | To which item it meets | paragraph 31 | ||
| Statement | 1.Date of the board of directors submitted or approved:2023/11/03 2.Date of the audit committee approved:2023/11/03 3.Start and end dates of financial reports or unaudited financial information of the reporting period:2023/01/01~2023/09/30 4.Operating revenue accumulated from 1/1 to end of the period (thousand NTD):3,860,775 5.Gross profit (loss) from operations accumulated from 1/1 to end of the period (thousand NTD):2,410,664 6.Net operating income (loss) accumulated from 1/1 to end of the period (thousand NTD):1,083,786 7.Profit (loss) before tax accumulated from 1/1 to end of the period (thousand NTD):1,192,424 8.Profit (loss) accumulated from 1/1 to end of the period (thousand NTD):938,278 9.Profit (loss) during the period attributable to owners of parent accumulated from 1/1 to end of the period (thousand NTD):923,710 10.Basic earnings (loss) per share accumulated from 1/1 to end of the period (NTD):3.71 11.Total assets end of the period (thousand NTD):9,956,871 12.Total liabilities end of the period (thousand NTD):3,556,413 13.Equity attributable to owners of parent end of the period (thousand NTD):5,822,320 14.Any other matters that need to be specified:None |
||||